Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial

---

Raghu G., Million-Rousseau R., Morganti A., Perchenet L., Behr J.

EUROPEAN RESPIRATORY JOURNAL, vol.42, no.6, pp.1622-1632, 2013 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 42 Issue: 6
• Publication Date: 2013
• Doi Number: 10.1183/09031936.00104612
• Journal Name: EUROPEAN RESPIRATORY JOURNAL
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.1622-1632
• Open Archive Collection: AVESIS Open Access Collection
• Ankara University Affiliated: No

Abstract

Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis.